Bristol-Myers wirbt bei Aktionären um Celgene-Übernahme

Frankfurt (Reuters) – Der US-Pharmakonzern Bristol-Myers Squibb hat die geplante 74 Milliarden Dollar schwere Übernahme des Biotechunternehmens Celgene verteidigt. Für Bristol-Myers sei das der …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
626